SIEMENS Healthineers
Siemens Healthcare Diagnostics Inc.

Urgent Field Safety Notice

CC 19-04.A-2.OUS

December, 2018

Atellica® IM

Atellica IM Anti-Thyroglobulin (aTG) Positive Bias

Our records indicate that your facility may have received the following product:

Table 1. Atellica IM Affected Product(s)

Assay	Siemens Material Number (SMN)	Lot Number	Expiration Date (YYYY-MM-DD)	1st Distribution Date (YYYY-MM-DD)
Atellica IM aTG (100 test kit)	10995461	72259303 87903305 94908307 96439307 16824309 25822309 28942311 55978313 70389317	2018-12-13 2019-01-12 2019-02-11 2019-02-11 2019-03-14 2019-03-14 2019-04-27 2019-05-27 2019-06-29	2018-04-03 2018-04-23 2018-05-03 2018-05-21 2018-06-21 2018-08-16 2018-07-25 2018-09-13 2018-10-11
Atellica IM aTG (500 test kit)	10995462	56683313 70390317	2019-05-27 2019-06-29	2018-10-16 2018-10-24

Reason for Urgent Field Safety Notice

The purpose of this communication is to inform you of an issue with the products indicated in Table 1 above and provide instructions on actions that your laboratory must take.

Siemens identified a positive bias with Atellica IM aTG kit lots ending in 317 and lower when compared to the standardization to World Health Organization (WHO) Reference Preparation MRC 65/93 stated in the Instructions for Use (IFU). See Additional Information, “Traceability to WHO MRC 65/93”.

Traceability to WHO Reference Preparation MRC 65/93 is restored with the release of Atellica IM aTG kit lots ending in 319 and higher (available in December 2018). As stated in the IFU, the theoretical WHO International units (IU/mL) is on average 3-fold higher than Siemens Healthcare Diagnostics standardization. Moving forward, this traceability will be maintained through enhancements to the control system.

Customers will observe a negative shift in patient results when transitioning from Atellica IM aTG reagent kit lots 317 and lower to Atellica IM aTG reagent kit lots 319 and higher. See Additional Information, Method Comparison.

511 Benedict Avenue
Tarrytown, New York 10591

The Atellica IM aTG assay remains “lot-locked”. Reagent lots must be used with specific lots of Atellica IM Calibrator 1, Atellica IM aTG 1, 2 Quality Control Material, and Atellica IM aTG Master Curve Material as noted on the notecard contained in each reagent kit.

Risk to Health

Use of lots affected by this issue may cause misinterpretation of antibody status for patients whose results are truly below but approaching the cut-off (60 U/mL per the IFU). Anti-thyroglobulin results would not be used in isolation, but rather would be used in conjunction with results of other thyroid tests. Therefore, Siemens is not recommending a review of previously generated results.

Actions to be Taken by the Customer

- Please review this letter with your Medical Director.
- You may continue use of Atellica IM aTG kit lots in Table 1 until you receive replacement product in your laboratory. Refer to Figure 1 and Figure 2 for Atellica IM aTG bias information.
- If you are currently using Atellica IM aTG kit lots in Table 1, review your inventory of these products as well as the associated Calibrator 1, aTG QC and aTG Master Curve Material and order replacement product by completing the Field Correction Effectiveness Check Form attached to this letter.
- Upon receipt of replacement product in your laboratory, discontinue use of and discard the Atellica IM aTG kit lots listed in Table 1. Refer to Figures 3 through 5 for expected results with replacement lots.
- Complete and return the Field Correction Effectiveness Check Form attached to this letter within 30 days.
- If you have received any complaints of illness or adverse events associated with the products listed in Table 1, immediately contact your local Siemens Customer Care Center or your local Siemens technical support representative.

Please retain this letter with your laboratory records, and forward this letter to those who may have received this product.

We apologize for the inconvenience this situation may cause. If you have any questions, please contact your Siemens Customer Care Center or your local Siemens technical support representative.

Additional Information

Traceability to WHO MRC 65/93

Figures 1 and 2 show the results obtained (“Observed”) as compared to the internal standards traceable to WHO MRC 65/93 (“Expected”) for Atellica IM aTG reagent kit lots ending in 311 and 317. Kit Lots ending in 311 are included to demonstrate the largest differences observed as compared to kit lots ending in 319. Kit lots ending in 317 are included as the most recently released lots.

511 Benedict Avenue
Tarrytown, New York 10591

Figure 1: Atellica IM- Reagent Lot 311 Observed vs Expected





Figure 2: Atellica IM- Reagent Lot 317 Observed vs Expected





511 Benedict Avenue
Tarrytown, New York 10591

Performance Characteristics

Siemens completed internal testing to evaluate the performance of Atellica IM aTG reagent kit lots ending in 311 and 317 when compared to Atellica IM aTG kit lots ending in 319. Kit Lots ending in 311 are included to demonstrate the largest differences observed as compared to kit lots ending in 319. Kit lots ending in 317 are included as the most recently released lots.

Limit of Detection (LoD)

LoD studies were performed on Atellica IM aTG kit lots ending in 311, 317 and 319 following Clinical and Laboratory Standards Institute (CLSI) Guidance EP17-A2 "Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures". Data from the LoD studies verified that the assay performs as described in the Instructions for Use.

Expected Values

Testing was performed following CLSI Guidance EP28-A3c "Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory", using 198 euthyroid patient samples to verify the cut-off stated in the IFU (60 U/mL). All samples included in this study had normal Thyroid-stimulating Hormone (TSH) values. The results in Table 2 demonstrate equivalent performance across lots. As with all in vitro diagnostic assays, each laboratory should determine its own reference range(s) for the diagnostic evaluation of patient results.

Table 2.Verification of Euthyroid Cut-off

	Kit Lots Ending in		
	311	**317**	**319**
Atellica IM %< 60 U/mL (n < 60 U/mL)	94% (186)	94% (186)	94% (187)

Method Comparison

Siemens completed internal testing to evaluate the performance of Atellica IM aTG kit lots ending in 319 compared to earlier reagent lots. Figure 3 through Figure 5 provide the performance data assessments listed in Table 3 comparing kit lots ending in 318 to kit lots ending in 311 and 317. The graphs show the shift that is expected when transitioning to the new reagent lots.

Table 3. Atellica IM Method Comparison Assessments

Figure	Assessment	Reagent Lots
3	Method Comparison	Lot 319 (y) vs. Reference Lot 311 (x)
	Difference Plot	
4	Method Comparison	Lot 319 (y) vs. Reference Lot 317 (x)
	Difference Plot	
5	Method Comparison	Atellica IM Lot 319 (y) vs. ADVIA Centaur XP Lot 318 (x) The ADVIA Centaur XP data is representative of the performance seen on the ADVIA Centaur, ADVIA Centaur XP and ADVIA Centaur XPT systems.
	Difference Plot	

511 Benedict Avenue
Tarrytown, New York 10591

Figure 3: Atellica IM- Reagent Lot 319 vs. Reagent Lot 311





511 Benedict Avenue
Tarrytown, New York 10591

Figure 4: Atellica IM- Reagent Lot 319 vs. Reagent Lot 317





Figure 5: Atellica IM Reagent Lot 319 vs. ADVIA Centaur XP Reagent Lot 318





Atellica IM is a trademark of Siemens Healthcare Diagnostics

511 Benedict Avenue
Tarrytown, New York 10591

FIELD CORRECTION EFFECTIVENESS CHECK

Atellica IM Anti-Thyroglobulin (aTG) Positive Bias

This response form is to confirm receipt of the enclosed Siemens Healthcare Diagnostics Urgent Field Safety Notice CC 19-04.A-2.OUS dated December, 2018 regarding Atellica IM Anti-Thyroglobulin (aTG) Positive Bias. Please read each question and indicate the appropriate answer.

Return this completed form to Siemens Healthcare Diagnostics as per the instructions provided at the bottom of this page.

1. I have read and understood the Urgent Field Safety Notice instructions provided in this letter. Yes ☐ No ☐

2. Do you now have any of the noted product(s) on hand? Please check inventories before answering. Yes ☐ No ☐

   If the answer to the question above is yes, please complete the table below to indicate the quantity of affected product in your laboratory and replacement product required.

Product Description **REF and Lot #**	**Quantity Discarded/** **Replacement Quantity Required**
Atellica IM aTG (100 test kit) REF 10995461 Kit Lots ending in 317 or lower	
Atellica IM aTG (500 test kit) REF 10995462 Kit Lots ending in 317 or lower	
Atellica IM Calibrator 1 REF 10995493 Kit Lots ending in 117 or lower	
Atellica IM aTG QC REF 10995465 Lots 8507591/8507592; 8510291/8510292; 8514591/8514592; 8517291/8517292; 8522491/8522492; 8524591/8524592; 8533991/8533992	
Atellica IM aTG Master Curve Material REF10995464 Lot 12789; 54247; 67408; 68888; 04650; 04652; 31778	

Name of person completing questionnaire:

Title:

Institution: Instrument Serial Number:

Street:

City: State:

Phone: Country:

Customer Sold To #: Customer Ship To #:

Please send a scanned copy of the completed form via email to XXXX@XXXX.
Or to fax this completed form to the Customer Care Center at XXXXXX.
If you have any questions, contact your local Siemens technical support representative.

511 Benedict Avenue
Tarrytown, New York 10591